SEC Form 4 · accession 0001638599-17-000180
ALBANY MOLECULAR RESEARCH INC · AMRI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher M. Conway
Officer — SVP, Discovery and Development
Period of report
Feb 8, 2017
Accepted (ET)
Feb 10, 2017 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001065087
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 8, 2017 | A | 4,278 | $0.00 | A | 42,291 | D | |
| Common Stock | Feb 8, 2017 | A | 3,210 | $0.00 | A | 45,501 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $18.41 | Feb 8, 2017 | A | 21,056 | A | — | Feb 8, 2027 | Common Stock | 21,056 | 21,056 | D |
Explanation of responses
- F1Option is exercisable as to 1/4th of the shares annually on the anniversary date of the grant for each of the next four years.